Cargando…

Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial

BACKGROUND: The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ju Yup, Kim, Nayoung, Park, Kyung Sik, Kim, Hyun Jin, Park, Seon Mee, Baik, Gwang Ho, Shim, Ki-Nam, Oh, Jung Hwan, Choi, Suck Chei, Kim, Sung Eun, Kim, Won Hee, Park, Seon-Young, Kim, Gwang Ha, Lee, Bong Eun, Jo, Yunju, Hong, Su Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962407/
https://www.ncbi.nlm.nih.gov/pubmed/27460100
http://dx.doi.org/10.1186/s12876-016-0490-8
_version_ 1782444828749987840
author Lee, Ju Yup
Kim, Nayoung
Park, Kyung Sik
Kim, Hyun Jin
Park, Seon Mee
Baik, Gwang Ho
Shim, Ki-Nam
Oh, Jung Hwan
Choi, Suck Chei
Kim, Sung Eun
Kim, Won Hee
Park, Seon-Young
Kim, Gwang Ha
Lee, Bong Eun
Jo, Yunju
Hong, Su Jin
author_facet Lee, Ju Yup
Kim, Nayoung
Park, Kyung Sik
Kim, Hyun Jin
Park, Seon Mee
Baik, Gwang Ho
Shim, Ki-Nam
Oh, Jung Hwan
Choi, Suck Chei
Kim, Sung Eun
Kim, Won Hee
Park, Seon-Young
Kim, Gwang Ha
Lee, Bong Eun
Jo, Yunju
Hong, Su Jin
author_sort Lee, Ju Yup
collection PubMed
description BACKGROUND: The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-line H. pylori treatment was compared with 10-day sequential therapy. METHODS: In total, 390 H. pylori-infected subjects participated in the randomized clinical trial: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days) or 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day). (13)C-urea breath test, rapid urease testing, or histology was performed to check for eradication. RESULTS: Intention-to-treat (ITT) eradication rates of 10-day sequential and 14-day quadruple therapy were 74.6 % and 68.7 %, respectively, and the per-protocol (PP) rates were 84.2 and 76.5 %, respectively. The eradication rate was higher in the sequential therapy group, but neither the ITT nor the PP analyses had a significant difference (P = 0.240 and P = 0.099, respectively). However, the adverse events were significantly lower in the modified bismuth quadruple therapy group than the sequential therapy group (36.9 vs. 47.7 %, P = 0.040). CONCLUSIONS: Ten-day sequential therapy appears to be more effective despite frequent adverse events. However, both 10-day SQT and 14-day PBAT did not reach the excellent eradication rates that exceed 90 %. Additional trials are needed to identify a more satisfactory first-line eradication therapy. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02159976); Registration date: 2014-06-03, CRIS (KCT0001176); Registration date: 2014-07-23. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-016-0490-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4962407
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49624072016-07-28 Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial Lee, Ju Yup Kim, Nayoung Park, Kyung Sik Kim, Hyun Jin Park, Seon Mee Baik, Gwang Ho Shim, Ki-Nam Oh, Jung Hwan Choi, Suck Chei Kim, Sung Eun Kim, Won Hee Park, Seon-Young Kim, Gwang Ha Lee, Bong Eun Jo, Yunju Hong, Su Jin BMC Gastroenterol Research Article BACKGROUND: The <80 % Helicobacter pylori eradication rate with sequential therapy is unsatisfactory. Modified bismuth quadruple therapy, replacing metronidazole with amoxicillin, could be promising because H. pylori resistance to tetracycline or to amoxicillin is relatively low. A 14-day modified bismuth quadruple protocol as first-line H. pylori treatment was compared with 10-day sequential therapy. METHODS: In total, 390 H. pylori-infected subjects participated in the randomized clinical trial: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days) or 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day). (13)C-urea breath test, rapid urease testing, or histology was performed to check for eradication. RESULTS: Intention-to-treat (ITT) eradication rates of 10-day sequential and 14-day quadruple therapy were 74.6 % and 68.7 %, respectively, and the per-protocol (PP) rates were 84.2 and 76.5 %, respectively. The eradication rate was higher in the sequential therapy group, but neither the ITT nor the PP analyses had a significant difference (P = 0.240 and P = 0.099, respectively). However, the adverse events were significantly lower in the modified bismuth quadruple therapy group than the sequential therapy group (36.9 vs. 47.7 %, P = 0.040). CONCLUSIONS: Ten-day sequential therapy appears to be more effective despite frequent adverse events. However, both 10-day SQT and 14-day PBAT did not reach the excellent eradication rates that exceed 90 %. Additional trials are needed to identify a more satisfactory first-line eradication therapy. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02159976); Registration date: 2014-06-03, CRIS (KCT0001176); Registration date: 2014-07-23. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-016-0490-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-26 /pmc/articles/PMC4962407/ /pubmed/27460100 http://dx.doi.org/10.1186/s12876-016-0490-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lee, Ju Yup
Kim, Nayoung
Park, Kyung Sik
Kim, Hyun Jin
Park, Seon Mee
Baik, Gwang Ho
Shim, Ki-Nam
Oh, Jung Hwan
Choi, Suck Chei
Kim, Sung Eun
Kim, Won Hee
Park, Seon-Young
Kim, Gwang Ha
Lee, Bong Eun
Jo, Yunju
Hong, Su Jin
Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
title Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
title_full Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
title_fullStr Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
title_full_unstemmed Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
title_short Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial
title_sort comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of helicobacter pylori: a prospective, multi-center, randomized clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962407/
https://www.ncbi.nlm.nih.gov/pubmed/27460100
http://dx.doi.org/10.1186/s12876-016-0490-8
work_keys_str_mv AT leejuyup comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT kimnayoung comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT parkkyungsik comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT kimhyunjin comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT parkseonmee comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT baikgwangho comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT shimkinam comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT ohjunghwan comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT choisuckchei comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT kimsungeun comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT kimwonhee comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT parkseonyoung comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT kimgwangha comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT leebongeun comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT joyunju comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial
AT hongsujin comparisonofsequentialtherapyandamoxicillintetracyclinecontainingbismuthquadrupletherapyforthefirstlineeradicationofhelicobacterpyloriaprospectivemulticenterrandomizedclinicaltrial